Nervous System Neoplasms without MCC DRG Reimbursement

DRG 055 encompasses inpatient admissions for nervous system neoplasms without Major Complication or Comorbidity, focusing on cases of moderate clinical complexity. It matters for inpatient reimbursement because it groups clinically similar encounters to determine Medicare payment rates and influences revenue for hospitals providing neurosurgical and neuro-oncology services.

DRG 055 Overview

DRG 055 covers hospital admissions for primary nervous system neoplasms without Major Complication or Comorbidity, typically including straightforward brain and central nervous system tumor resections, biopsies, or related inpatient management when no major coexisting conditions are present. This Diagnosis-Related Group groups cases by similar clinical complexity and expected resource use, which determines base payment under Medicare inpatient prospective payment systems. Proper DRG assignment affects hospital reimbursement and payment accuracy for neurosurgery and neuro-oncology inpatient care.

Perioperative and intraoperative management studies assessing optimal surgical approaches and adjunct therapies for resection of primary brain neoplasms without major complications: these trials focus on comparing minimally invasive techniques, extent-of-resection strategies, and the use of intraoperative adjuncts (e.g., advanced mapping, fluorescence guidance) in adult patients with intracranial tumors that do not incur major comorbid complications. The patient population typically includes elective neurosurgical inpatients with confirmed CNS neoplasms who are hemodynamically stable and without MCCs; outcomes measured include extent of tumor removal, neurologic deficit rates, length of stay, and short-term readmission. This research is relevant to providers and payers because it directly affects acute hospitalization costs, resource utilization (operating room time, ICU use), and short-term functional outcomes that drive reimbursement and DRG grouping.
Comparative effectiveness studies of postoperative adjuvant strategies and timing for patients with nervous system neoplasms without MCC: these studies compare different sequences or intensities of adjuvant care (for example, early versus delayed initiation of radiotherapy or different fractionation schedules) in patients who undergo uncomplicated tumor resection and do not develop major in-hospital complications. The target population consists of postoperative inpatients transitioning to outpatient oncologic care, with endpoints including progression-free survival, neurologic functional scores, readmissions related to treatment toxicity, and total episode-of-care costs. Payers and hospital administrators value this research because it informs care pathways that can reduce avoidable readmissions and downstream spending while optimizing long-term outcomes within the DRG-defined episode.
Post-discharge outcomes and rehabilitation trials evaluating functional recovery, cognitive outcomes, and care coordination for patients discharged after hospitalization for nervous system neoplasms without MCC: these pragmatic studies enroll patients who had an uncomplicated inpatient stay and test interventions such as structured neuro-rehabilitation programs, remote monitoring, or bundled care coordination to improve return-to-function and reduce post-discharge complications. Populations include survivors of brain tumor resection with baseline functional deficits but no major in-hospital complications; measured outcomes include functional independence measures, unplanned post-discharge acute care use, quality of life, and total 30- to 90-day costs. This area is important to providers and payers because effective post-discharge strategies can decrease readmissions, improve functional outcomes, and influence total cost of care attributed to the DRG.

Perioperative and intraoperative management studies assessing optimal surgical approaches and adjunct therapies for resection of primary brain neoplasms without major complications: these trials focus on comparing minimally invasive techniques, extent-of-resection strategies, and the use of intraoperative adjuncts (e.g., advanced mapping, fluorescence guidance) in adult patients with intracranial tumors that do not incur major comorbid complications. The patient population typically includes elective neurosurgical inpatients with confirmed CNS neoplasms who are hemodynamically stable and without MCCs; outcomes measured include extent of tumor removal, neurologic deficit rates, length of stay, and short-term readmission. This research is relevant to providers and payers because it directly affects acute hospitalization costs, resource utilization (operating room time, ICU use), and short-term functional outcomes that drive reimbursement and DRG grouping.
Comparative effectiveness studies of postoperative adjuvant strategies and timing for patients with nervous system neoplasms without MCC: these studies compare different sequences or intensities of adjuvant care (for example, early versus delayed initiation of radiotherapy or different fractionation schedules) in patients who undergo uncomplicated tumor resection and do not develop major in-hospital complications. The target population consists of postoperative inpatients transitioning to outpatient oncologic care, with endpoints including progression-free survival, neurologic functional scores, readmissions related to treatment toxicity, and total episode-of-care costs. Payers and hospital administrators value this research because it informs care pathways that can reduce avoidable readmissions and downstream spending while optimizing long-term outcomes within the DRG-defined episode.
Post-discharge outcomes and rehabilitation trials evaluating functional recovery, cognitive outcomes, and care coordination for patients discharged after hospitalization for nervous system neoplasms without MCC: these pragmatic studies enroll patients who had an uncomplicated inpatient stay and test interventions such as structured neuro-rehabilitation programs, remote monitoring, or bundled care coordination to improve return-to-function and reduce post-discharge complications. Populations include survivors of brain tumor resection with baseline functional deficits but no major in-hospital complications; measured outcomes include functional independence measures, unplanned post-discharge acute care use, quality of life, and total 30- to 90-day costs. This area is important to providers and payers because effective post-discharge strategies can decrease readmissions, improve functional outcomes, and influence total cost of care attributed to the DRG.

OpenPayer

Summary & Overview

Nervous System Neoplasms without Major Complication or Comorbidity: Inpatient Reimbursement Overview

DRG 055 Overview

Clinical Trials

Related Codes

Clinical Trials

Related Codes